| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MADISON, Wisc.—Bioinformatics specialist DNASTAR announced the introduction of a small-college grant program designed to help academic institutions perform at the same level as larger colleges. Under the Rising Star program, for which the company has initially set aside $100,000, colleges can receive up to $2500 in matching funds toward the purchase of the company's Lasergene sequence analysis software.
 
"The goal of this program is to ensure that all colleges and universities, regardless of size or availability of resources, have access to state-of-the-art bioinformatics research tools," said Dr. Fred Blattner, a geneticist at the University of Wisconsin and a founder of DNASTAR. "We have always tried to be innovative when it comes to supporting the academic research community in genomics. The Rising Star initiative will permit us to reach out to those smaller institutions whose primary focus is teaching."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue